Many of the most active people in Honolulu are over 60: golfers on windward courses, hikers on ridgeline trails, paddlers on weekend runs. When joint pain starts to interrupt that life, regenerative medicine often comes up, and so does a common worry: does it even work as well at my age? This article sorts the newest 2026 research on PRP and cell-based therapy for people over 60, in plain language.
11
randomized trials in a 2026 PRP meta-analysis that flagged age as a factor
28
RCTs and 3,246 patients in a 2025 PRP meta-analysis, largely older adults
2026
study finding chronological age did not determine 12-month cell-therapy response
Age affects how tissue heals, so it is reasonable to wonder whether a regenerative injection works the same way at 65 as it does at 45. The newest research suggests the honest answer is nuanced: PRP outcomes do appear to differ by age in some studies, while cell-based therapy outcomes may depend less on chronological age and more on the condition of the joint and the treatment itself.
A 2026 systematic review and meta-analysis of 11 randomized trials covering 851 patients looked at PRP for knee, hip, and post-traumatic osteoarthritis. PRP significantly improved WOMAC scores overall, but a subgroup analysis identified age as a significant factor: patients under 60 improved more than patients 60 and older. That does not mean PRP fails after 60. A 2025 meta-analysis of 28 randomized trials and 3,246 patients, largely an older population, found PRP comparable to hyaluronic acid injections for pain relief. The fair summary is that PRP remains a reasonable option for many people over 60, with expectations set honestly.
“A 2026 meta-analysis of 11 randomized trials found PRP significantly improved outcomes in osteoarthritis overall, with a subgroup analysis showing greater improvement in patients under 60 than in those 60 and older.”
For cell-based therapy, the picture is different. A 2026 study of 12-month pain outcomes after autologous fat-derived stromal vascular fraction injection for knee osteoarthritis found that chronological age was not a determinant of response; what mattered more were the metabolic burden, the structural severity of the arthritis, and the cell dose delivered. A separate large real-world case series with two-year follow-up likewise concluded that patient age and BMI did not drive clinical outcomes. This is early evidence, but it challenges the assumption that being older automatically disqualifies someone from benefit.
“A 2026 study found chronological age was not a determinant of 12-month pain response after autologous fat-derived cell therapy for knee osteoarthritis; structural severity and cell dose mattered more.”
The practical takeaway for an active person over 60 is that regenerative options are not automatically off the table, but the decision depends on your specific joint, its imaging, your health more broadly, and the treatment being discussed. Equally important, the research is clear that injections are companions to, not substitutes for, strength training, walking programs, and good load management, the things that keep Honolulu residents on the trail and on the water for decades.
A note from the clinic
Age is part of the picture, but it is not the whole story. At Aloha Stem Cell in Honolulu we evaluate each person's joint, imaging, and goals carefully, and we will tell you honestly whether a regenerative treatment is a good fit at any age, or whether something else serves you better. Call (808) 593-2525 to start the conversation.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.